296 related articles for article (PubMed ID: 10604122)
1. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers in neuroendocrine tumors.
Eriksson B; Oberg K; Stridsberg M
Digestion; 2000; 62 Suppl 1():33-8. PubMed ID: 10940685
[TBL] [Abstract][Full Text] [Related]
3. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.
Tomassetti P; Migliori M; Lalli S; Campana D; Tomassetti V; Corinaldesi R
Ann Oncol; 2001; 12 Suppl 2():S95-9. PubMed ID: 11762360
[TBL] [Abstract][Full Text] [Related]
5. [Chromogranin A: a marker of neuroendocrine tumors].
D'Herbomez M; Gouze V
Ann Biol Clin (Paris); 2002; 60(6):641-6. PubMed ID: 12446227
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
7. Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha).
Dirnhofer S; Freund M; Rogatsch H; Krabichler S; Berger P
Hum Pathol; 2000 Aug; 31(8):966-72. PubMed ID: 10987258
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Kanakis G; Kaltsas G
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):791-802. PubMed ID: 23582919
[TBL] [Abstract][Full Text] [Related]
9. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A, neuron-specific enolase and synaptophysin as neuroendocrine cell markers in the diagnosis of tumours of the gastro-entero-pancreatic system.
Schürmann G; Betzler M; Buhr HJ
Eur J Surg Oncol; 1990 Aug; 16(4):298-303. PubMed ID: 2116326
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
12. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
13. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
16. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
17. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.
Wilander E; Lundqvist M; Oberg K
Prog Histochem Cytochem; 1989; 19(2):1-88. PubMed ID: 2662260
[TBL] [Abstract][Full Text] [Related]
20. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]